ViiV Healthcare : FDA Approves Apretude, Long-acting Injectable Option For HIV Prevention

How will Omicron fearful market fare?

Although market experts don’t rule out more pain going forward, they are hopeful that valuation comfort after correction could make Indian equities more attractive.

Apart from clarity on Omicron and central bank stance, whether earnings growth sustains will be crucial to determining how Indian equity markets fare in the days to come.

Rupee gains 17 paise in early trade

However, surging crude prices restricted the Indian currency’s gain.

The rupee appreciated 17 paise to 75.73 against the US dollar in the opening session on Tuesday, December 21, 201, tracking heavy buying in domestic equities and a weak American currency in the overseas market.

However, surging crude prices restricted the rupee’s gain, traders said.

At the interbank foreign exchange, the rupee opened strong at 75.74 and inched up to quote 75.73 against the American dollar in early deals, registering a rise of 17 paise from the last close.

In the previous session, the rupee had settled at 75.90 against the greenback.

On the domestic equity market front, the 30-share Sensex was trading 720.07 points or 1.29 per cent higher at 56,542.08, while the broader NSE Nifty advanced 215.10 points or 1.29 per cent to 16,829.30.

The dollar index, which gauges the greenback’s strength against a basket of six currencies, fell 0.06 per cent to 96.49.

Brent crude futures, the global oil benchmark, increased 0.80 per cent to USD 72.09 per barrel.

Foreign institutional investors (FIIs) remained net sellers in the capital markets, pulling out ₹3,565.36 crore on Monday, as per provisional data.

Sanofi To Buy Amunix For An Upfront Payment Of $1 Bln – Quick Facts

French drug major Sanofi (SNYNF,SNY) announced Tuesday that it has entered into an agreement to acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company.

Under the deal terms, Sanofi will acquire Amunix for an upfront payment of approximately $1 billion and up to $225 million upon achievement of certain future development milestones.

The closing of the deal is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary closing conditions. Sanofi expects to complete the acquisition in the first quarter of 2022.

Sanofi said the acquisition supports its efforts to accelerate and expand its contributions to innovative medicines for oncology patients, with approximately 20 molecules currently in development.

Amunix’s proprietary XTEN masks and cleavable linkers are a next-generation protein engineering approach. They allow biologics to circulate in “stealth” mode, becoming active preferentially in disease specific micro-environments, with the aim to enable safer?and?more efficacious?medicines.

Amunix’s pipeline includes lead candidate, AMX-818, a masked HER2-directed TCE, which offers a strong strategic fit with Sanofi’s focus on developing potentially transformative cancer therapies in immuno-oncology.

In the deal, Weil, Gotshal & Manges LLP is acting as Sanofi’s legal counsel. Centerview Partners LLC is acting as financial advisor to Amunix.

How will Omicron fearful market fare?

Although market experts don’t rule out more pain going forward, they are hopeful that valuation comfort after correction could make Indian equities more attractive.

Apart from clarity on Omicron and central bank stance, whether earnings growth sustains will be crucial to determining how Indian equity markets fare in the days to come.

Crossword Cybersecurity Proposes To Buy A Cyber Threat Co. For 1.5 Mln Pounds

Crossword Cybersecurity Plc (CCS.L), a cyber security and risk management company on Tuesday announced that it has signed heads of terms to acquire a cyber threat company for a total consideration of 1.5 million pounds, in cash and stock; part upfront and part deferred.

The acquisition agreement is expected to be signed in early 2022. The acquisition would bring Crossword’s portfolio to five cyber security offerings besides its cyber security consulting business. The acquisition is also expected to bring additional SaaS products which claims to provide clients with high value cyber security insight at an affordable cost. It would also bring circa twenty new clients to Crossword, across various sectors in multiple jurisdictions.

Crossword also said on the back of a successful 2021, with revenue growth achieved expected to be over 40 percent, at the lower end of market expectations, it sees accelerated revenue growth in 2022.

Shares of Crossword Cybersecurity closed Monday’s trading at 33 pounds.

ViiV Healthcare : FDA Approves Apretude, Long-acting Injectable Option For HIV Prevention

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK,GSK.L), with Pfizer Inc. (PFE) and Shionogi Limited as shareholders, said that the US Food and Drug Administration approved Apretude, long-acting injectable pre-exposure prophylaxis option to reduce the risk of sexually acquired HIV-1.

The long-acting injectable was approved for use in adults and adolescents weighing at least 35 kg who are at risk of sexually acquiring HIV and who have a negative HIV-1 test prior to initiation.

Apretude is administered as a single 600 mg (3-ml) intramuscular (IM) injection of cabotegravir in the buttocks by a health care provider every two months after two initiation injections administered one month apart and an optional oral lead-in to assess tolerability.

ViiV Healthcare noted that it will begin shipping Apretude to wholesalers and specialty distributors in the US in early 2022. ViiV Healthcare has initiated submissions to other regulatory authorities. Apretude has not been approved or licensed anywhere outside of the US for use in HIV prevention.